Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis

The aim of this randomized, controlled study was to evalaute effects of 12 months alendronate therapy on bone mineral density (BMD) and markers of bone formation and resorption in women with postmenopausal osteoporosis. Study enrolled women with BMD at least 2 SD below adult, premenopausal BMD mean. Patients to be treated were randomized into two groups. Patients in the control group received 500 mg elemental calcium tablet daily and treatment group received 10 mg/day alendronate and 500 mg elemental calcium tablet for twelve months. Pretreatment characteristics of patients in both groups were similar. A significant increase in BMD of the treatment group patients compared to control group was observed at 12 months (p < 0.001). Markers of bone formation and resorption in the treatment group reduced significantly at 6 and 12 months of therapy compared to control group (p < 0.001)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis

The objective of this blind, randomized controlled study was to evaluate effect of 12 months alendronate treatment on bone mineral density (BMD) and bone formation, resorption markers in postmenopausal osteoporotic women. Women with BMD values at least 2 standard deviations (SD) below BMD of adult premenopousal women were included in the study. Patients were randomized into two groups. The control group (n=ll2) received 500 mg daily elemental calcium, while the treatment group (n=l58) received 10 mg alendronate plus 500 mg daily elemental calcium for 12 months. Patient demographics were comparable in both groups before treatment. After 12 months, BMD of patients in alendronate group was increased significantly as compared to BMD before treatment and BMD in control group (p<0.001) . Increase in BMD was apparent in all measured sites but highest values were attained in the Ll-L4 region with 4.8 %. Bone formation and resorption parameters showed significant decrease in the 6 th and 12 th months of treatment as compared to control group and values before treatment (-23.1% to - 50.6 %). As a conclusion, twelve months treatment of alendronate (10 mg/day) in postmenopausal osteoporotic women causes a significant increase of BMD in all measurement sites, as compared to BMD values before treatment and BMD of control group. Likewise bone formation and resorption markers showed significant decrease in the 6 th and 12 th months of treatment as compared to values in the control group and values before treatment